Abstract
Beta cell replacement therapy is a proven strategy to restore glycemic control, reduce hypoglycemic awareness and stabilize glycated hemoglobin (HbA1c) for a subset of patients with type 1 diabetes. However, the absence of an effective strategy to prevent islet allograft rejection and recurrent autoimmunity restricts patient inclusion and durable insulin independence. Herein, we explore the utility of islet graft localized cyclosporine A (CsA) delivery via co-transplanted drug-eluting poly(lactic-co-glycolic acid) (PLGA) microparticles to attenuate allograft rejection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
